Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Q3 2024 Earnings Conference Call November 13, 2024 4:30 PM ET
Company Participants
David Nakasone - Head, IR
Bobby Azamian - Chairman & CEO
Aziz Mottiwala - Chief Commercial Officer
Jeff Farrow - CFO and CSO
Sesha Neervannan - COO
Elizabeth Yeu - Chief Medical Officer
Conference Call Participants
Eddie Hickman - Guggenheim Securities
Lachlan Hanbury-Brown - William Blair
Andrea Newkirk - Goldman Sachs
Oren Livnat - HC Wainwright
Balaji Prasad - Barclays
Jason Gerberry - Bank of America Merrill Lynch
Corey Jubinville - Life Sci Capital
Francois Brisebois - Oppenheimer
Operator
Welcome to Tarsus' Third Quarter 2024 Financial Results Conference Call. As a reminder, this call is being recorded at this time, I would like to turn the call over to David Nakasone, Head of Investor Relations, to lead off the call. David, you may begin. Thank you.
David Nakasone
Before we begin, I encourage everyone to go to the investor section of the Tarsus website to view the earnings release and related materials we will be discussing today. Joining me on the call this afternoon, are Bobby Azamian, our Chief Executive Officer and Chairman, Aziz Mottiwala, our Chief Commercial Officer, Sesha Neervannan, our Chief Operating Officer, Jeff Farrow, our Chief Financial Officer and Chief Strategy Officer, and joining us for the first time, Dr Elizabeth Yeu, our newly appointed Chief Medical Officer for the Q&A portion.
I'd like to draw your attention to slide three, which contains our forward looking statements. During this call, we will be making forward looking statements that are based on our current expectations and beliefs, these statements are subject to certain risks and uncertainties, and our actual results may differ materially. I encourage you to consult the risk factors contained in our SEC filings for additional detail.
With that, I will turn the call over to Bobby.
Bobby Azamian
Good afternoon, everyone and thank you for joining us. 2024 continues to be a year of tremendous growth for Tarsus as we execute on our vision to revolutionize treatments for patients in need, and I am pleased to share the results of our most successful quarter to date.
In the fourth full quarter of our launch, we generated more than $48 million in XDEMVY net product sales driven by more than 41,000 bottles delivered to patients impacted by demodex blepharitis or DB. As the launch continues to accelerate, we are even more confident in the potential of XDEMVY. This confidence stems from continuing to deliver on our strategy and adhering to our category creating fundamentals. We are executing on all fronts with a sharp focus on education, ease of access and even more evidence generation to come. We expanded our sales force from approximately 100 to 150 at the end of the third quarter, and we are starting to see a meaningful increase in the number of eye care professionals, or ECPs prescribing XDEMVY as well as the number of ECPs who write multiple times a week, a leading indicator that depth of prescribing is trending in the right direction. One of my passions as CEO is remaining connected to the field and engaging with ECPs in their clinics. In my most recent field visit, I met with one of our top prescribers, and saw firsthand the power of repeat interactions in further deepening the use of extend XDEMVY and DB patients. These repeat visits, combined with ease of access and shared evidence, are accelerating that prescribers desire to look for and treat DB in all of their patients.